Kelly George supports clients in navigating the FDA policy environment for drugs, biologics, and medical devices. She applies scientific and regulatory understanding to overarching drug development strategies towards establishing quality, safety and efficacy for FDA products (pre/post)approval while balancing the impact on patient access, time to market entry, cost of drug development, and the creation of a sustainable market.
Prior to joining Avalere, Kelly focused on pipeline technologies in pre-FDA approval phases of development at the Innovation Institute. Before that, she worked as a scientific consultant with Fourth River Solutions where she focused on business strategy development and in-depth market analysis.
Kelly has a PhD in bioanalytical chemistry from the University of Pittsburgh, a BS in biology from James Madison University and a regulatory affairs certification.
For even deeper coverage, download the 2021 Healthcare Industry Outlook document below.